Objectives: This retrospective study used various indices to evaluate remission and low disease activity in ‘real life’ patients with rheumatoid arthritis (RA), given antitumour necrosis factor (anti-TNF) as a first-line treatment; changes in concomitant steroid and conventional synthetic disease-modifying antirheumatic drug (csDMARD) treatment were also assessed. Methods: Remission and low disease activity were analysed in patients with RA treated with anti-TNF using the 28-joint Disease Activity Score (DAS28), Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI). Remission and low disease activity were recorded after 6 months, 1 year and 2 years, along with concomitant prednisone and csDMARD treatment. Results: A total of 271 patients with RA were included in the study. After 6 months, remission rates were 18.0%, 20.3% and 23.0% as assessed by CDAI, SDAI and DAS28, respectively. After 1 year and 2 years, respectively, remission rates were 18.4% and 15.9% using CDAI, 21.8% and 17.3% using SDAI, and 22.1% and 17.3% using DAS28. Low disease activity was achieved in 30–40% of patients, depending on the indices used. There was a significant reduction in the number of patients on prednisone and csDMARDs during anti-TNF treatment. Conclusion: Remission with first-line anti-TNF treatment is an achievable goal in clinical practice, allowing a reduction in concomitant csDMARD and prednisone treatment.

Conigliaro, P., Chimenti, M.s., Triggianese, P., Ballanti, E., Sunzini, F., Duca, I., et al. (2016). Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 44(1_suppl), 90-94 [10.1177/0300060515593262].

Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor

CONIGLIARO, PAOLA;CHIMENTI, MARIA SOLE;TRIGGIANESE, PAOLA;BALLANTI, ELEONORA;PERRICONE, ROBERTO
2016-01-01

Abstract

Objectives: This retrospective study used various indices to evaluate remission and low disease activity in ‘real life’ patients with rheumatoid arthritis (RA), given antitumour necrosis factor (anti-TNF) as a first-line treatment; changes in concomitant steroid and conventional synthetic disease-modifying antirheumatic drug (csDMARD) treatment were also assessed. Methods: Remission and low disease activity were analysed in patients with RA treated with anti-TNF using the 28-joint Disease Activity Score (DAS28), Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI). Remission and low disease activity were recorded after 6 months, 1 year and 2 years, along with concomitant prednisone and csDMARD treatment. Results: A total of 271 patients with RA were included in the study. After 6 months, remission rates were 18.0%, 20.3% and 23.0% as assessed by CDAI, SDAI and DAS28, respectively. After 1 year and 2 years, respectively, remission rates were 18.4% and 15.9% using CDAI, 21.8% and 17.3% using SDAI, and 22.1% and 17.3% using DAS28. Low disease activity was achieved in 30–40% of patients, depending on the indices used. There was a significant reduction in the number of patients on prednisone and csDMARDs during anti-TNF treatment. Conclusion: Remission with first-line anti-TNF treatment is an achievable goal in clinical practice, allowing a reduction in concomitant csDMARD and prednisone treatment.
2016
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
English
Antitumour necrosis factor; disease-modifying antirheumatic drugs; low disease activity; remission; rheumatoid arthritis; Medicine (all); Biochemistry; Cell Biology; Biochemistry (medical)
http://imr.sagepub.com/content/by/year
Conigliaro, P., Chimenti, M.s., Triggianese, P., Ballanti, E., Sunzini, F., Duca, I., et al. (2016). Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 44(1_suppl), 90-94 [10.1177/0300060515593262].
Conigliaro, P; Chimenti, Ms; Triggianese, P; Ballanti, E; Sunzini, F; Duca, I; Perricone, R
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/165597
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact